Sun Pharma Shares Drop as USFDA Flags Key Baska Facility with OAI Status

• Sun Pharma shares fell 2.4% after the USFDA classified its Baska facility as Official Action Indicated (OAI).
• The Baska plant, inspected in September 2025, is crucial for Sun Pharma's new complex generics.
• OAI classification lowers the probability of positive surprises from the generic business but doesn't impact current forecasts.
• Other facilities like Halol and Mohali also face ongoing regulatory scrutiny from the USFDA.
• Despite regulatory challenges, Sun Pharma expects its India business to grow ahead of the market, driven by therapy focus and brand building.

Why It Matters: USFDA's OAI for Baska facility pressures Sun Pharma shares, despite strong India business outlook.